Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic and local tolerability study of inhaled dry powder amikacin via Cyclops in adults with drug-susceptible tuberculosis
NL-OMON55683Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of amikacin in Tuberculosis (TB) (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: Actual dose, AUC0-24 and 3 more. Started May 2020; status: active, not recruiting.
02
Drugs
amikacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON55683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55683.